Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4900-4905

  Chinsangaram, Jarasvech ^a   Honeychurch, Kady M ^a   Tyavanagimatt, Shanthakumar R ^a   Leeds, Janet M ^a   Bolken, Tove C ^a   Jones, Kevin F ^a   Jordan, Robert ^a,f   Marbury, Thomas ^b   Ruckle, Jon ^c,g   Mee Lee, Denis ^c,g   Ross, Eric ^d   Lichtenstein, Israel ^e   Pickens, Margaret ^e   Corrado, Michael ^e   Clarke, Jean M ^a   Frimm, Annie M ^a   Hruby, Dennis E ^a  

^a SIGA Technologies Incorporated   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

^c Hawaii Clinical Research Center   (United States)

^d Apex Research Institute   (United States)

^e SYNEOS HEALTH   (United States)

^f GILEAD SCIENCES   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TECOVIRIMAT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

EID: 84865404323     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00904-12     Document Type: Article

References (16)

1. Bailey TR, et al. 2007. N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl) carboxamides: identification of novel orthopoxvirus egress inhibitors. J. Med. Chem. 50:1442-1444. (Pubitemid 46564366)
2. Baker RO, Bray M, Huggins JW. 2003. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 57:13-23. (Pubitemid 36254717)
3. Bray M. 2003. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res. 58:101-114. (Pubitemid 36556213)
4. Bray M, Roy CJ. 2004. Antiviral prophylaxis of smallpox. J. Antimicrob. Chemother. 54:1-5. (Pubitemid 39028959)
5. Buller RM. 1999. Poxviruses. In Armstrong D, Cohen J (ed), Infectious diseases, p 8.7.4-8.7.6. Harcourt, London, United Kingdom.
6. Chen Y, et al. 2011. Comparison of the safety and pharmacokinetics of ST-246 after IV infusion or oral administration in mice, rabbits and monkeys. PLoS One 6(8):e23237. doi:10.1371/journal.pone.0023237.
7. Fenner F, Henderson DA, Arita I, Jazek Z, Ladnyi ID. 1988. Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
8. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. 2003. Smallpox vaccination: a review, part II. Adverse events. Clin. Infect. Dis. 37:251-271. (Pubitemid 36930357)
9. Henderson DA, et al. 1999. Smallpox as a biological weapon: medical and public health management. JAMA 281:2127-2137. (Pubitemid 29264692)
10. Jordan R, et al. 2009. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 53:1817-1822.
11. Jordan R, et al. 2008. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob. Agents Chemother. 52:1721-1727. (Pubitemid 351614665)
12. Kemper AR, Davis MM, Freed GL. 2002. Expected adverse events in a mass smallpox vaccination campaign. Eff. Clin. Pract. 5:84 -90.
13. LeDuc JW, Damon I, Relman DA, Huggins J, Jahrling PB. 2002. Smallpox research activities: U.S. interagency collaboration, 2001. Emerg. Infect. Dis. 8:743-745. (Pubitemid 34764747)
14. Panchanathan V, Chaudhri G, Karupiah G. 2006. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J. Virol. 80:6333- 6338.
15. Smith GL, McFadden G. 2002. Smallpox: anything to declare? Nat. Rev. Immunol. 2:521-527. (Pubitemid 37328743)
16. Yang G, et al. 2005. An orally bioavailable antipoxvirus compound (ST- 246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79:13139-13149. (Pubitemid 41433232)